Satiating Effects of Isolated Soy Proteins

Weight Management Clinical Trial

Official title:

Comparison of the Satiating Effects of Differentially Processed Isolated Soy Proteins

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01731197
• Other study ID #: GIL-1245
• Status: Completed
• Phase: N/A
• Start date: November 2012
• Est. completion date: November 2013

Study information

• Verified date: October 2019
• Source: DuPont Nutrition and Health
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Proteins are known to be more satiating than the other macronutrients; however, the type and amount of protein needed to induce a significant effect on satiety (fullness between meals) is sometimes difficult to determine. In this study, 2 differentially processed isolated soy proteins will be tested for satiety using subjective visual analogue scales. The amount of food consumed following intake of the isolated soy proteins will be measured 3 hours after consuming the proteins. The hypothesis is that differentially processed isolated soy proteins will show unique satiety responses.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: November 2013
• Est. primary completion date: June 2013
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• BMI between 20 and 30 kg/m2

• Age between 18-65y

• Unrestrained eater (score<12)

• Regularly consume 3 meals per day

• Moderate exercise (eg running, aerobics classes, other sports activities) of no more than 7 hours per week

Exclusion Criteria:

• use of drugs that influence carbohydrate or lipid metabolism (eg. hypoglycemic agents, antibiotics taken less than 6 weeks before study entry, glucocorticoids, anti-diarrheal medication, weight loss medication, and anti-diabetic medication)

• presence of any significant disease (eg gastrointestinal diseases, diabetes, a CVD event less than 12 weeks from study entry, current hepatic disease, etc)

• use of special dietary treatments within 4 weeks of study (eg weight loss diet, extremely high or low carbohydrate/protein/fat diet, use of meal replacements more than once a day)

• use of supplements within 1 week of study (does not include vitamin supplements or supplements which are routinely taken and were initiated 4 weeks before the study and which will be continued during the study period)

• restrained eater (score>12)

• weight change (absolute body weight change of = 10%) within the previous 6 weeks

• alcohol intake >2 drinks/day

• food allergies of any kind

• swallowing difficulties

• exercising more than 7 hours per week

Related Conditions & MeSH terms

• Weight Management

Intervention

Dietary Supplement:
• Dry-Blended Beverage

Locations

Country	Name	City	State
Canada	Glycemic Index Laboratories	Toronto	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
DuPont Nutrition and Health

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Subjective Satiety	Measure subjective satiety using visual analogue scales	3 hours
Secondary	Ad Libitum Food Intake	At the end of 3 hours after consuming test diets, measure the amount of food consumed for 30 mins	30 minutes